Author
Listed:
- Thibault Cousin
(CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen)
- Frederic Chantreuil
(UNC - Université de la Nouvelle-Calédonie, LARJE - Laboratoire de Recherches Juridique et Economique - UNC - Université de la Nouvelle-Calédonie)
- Eric Barat
(CHU Rouen - NU - Normandie Université)
- Olivier Boyer
(PANTHER - Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices - UNIROUEN - Université de Rouen Normandie - NU - Normandie Université - INSERM - Institut National de la Santé et de la Recherche Médicale, CHU Rouen - NU - Normandie Université)
- Francoise Norol
(CHU Pitié-Salpêtrière [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - SU - Sorbonne Université)
- Rémi Varin
(CHU Rouen - NU - Normandie Université)
- Isabelle Lebon
(CREM - Centre de recherche en économie et management - UNICAEN - Université de Caen Normandie - NU - Normandie Université - UR - Université de Rennes - CNRS - Centre National de la Recherche Scientifique)
- Camille Giverne
(PANTHER - Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices - UNIROUEN - Université de Rouen Normandie - NU - Normandie Université - INSERM - Institut National de la Santé et de la Recherche Médicale, CHU Rouen - NU - Normandie Université)
Abstract
Objectives: The therapeutic promises of somatic cell and gene therapy (Advanced Therapy Medicinal Products - ATMP) and the significant current or future costs of such therapies raise questions about the impact of European health policy on these expenses. Regulation 1394/2007 currently imposes the medicinal product status on many treatments derived from cell therapy. This study aims to determine the impact of new regulations on manufacturing costs of cell therapy treatments, used as ATMP. Methods: In our study, using counterfactual reasoning, we analyze the consequences that a change of status would have on the hematopoietic stem cells (HSC) used for treatment of leukemia. Results: Under the existing status of cell transplantation (CT, Directive 2004/23/EC), the annual production cost of these cell therapy products (CTP) in France is estimated at euro 5.6 million. If the HSC used in leukemia indication were under the medicinal product status of ATMP, the cost would rise to approximately euro 9.9 million, without accounting for expenses related to facilities, which are much higher for ATMP than for CT. Conclusion: This additional burden for manufacturers must be weighed against the theoretical benefits for patients, such as reduced contamination risk. Given the very low contamination levels reported by facilities using transplant standards, the extra cost seems excessive and could hinder the development of new advanced therapies. Furthermore, it raises the need to adapt existing Good Manufacturing Practice guidelines for autologous products or those made from a single donor for a single patient, ensuring safety and cost reduction, which should encourage further development of cell therapy.
Suggested Citation
Thibault Cousin & Frederic Chantreuil & Eric Barat & Olivier Boyer & Francoise Norol & Rémi Varin & Isabelle Lebon & Camille Giverne, 2025.
"Impact of Advanced Therapy Medicinal Products status in European regulations on their production cost: The case of hematopoietic stem cells,"
Post-Print
hal-04927306, HAL.
Handle:
RePEc:hal:journl:hal-04927306
DOI: 10.1016/j.pharma.2025.01.013
Download full text from publisher
To our knowledge, this item is not available for
download. To find whether it is available, there are three
options:
1. Check below whether another version of this item is available online.
2. Check on the provider's
web page
whether it is in fact available.
3. Perform a
search for a similarly titled item that would be
available.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-04927306. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.